Antibodies, Bispecific
- Name
- Antibodies, Bispecific
- Accession Number
- DBCAT005919
- Description
Not Available
- Drugs
Drug Drug Description Ertumaxomab Ertumaxomab is under investigation in clinical trial NCT00522457 (Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy). - Drugs & Drug Targets
Drug Target Type